Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABCD in Invasive Mold Disease
NCT07239765Phase 3Completed
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Jul 2021
- Primary completion
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of amphotericin b cholesteryl sulfate complex in Invasive mold disease (IMD), talaromycosis, sponsored by CSPC Ouyi Pharmaceutical. Started Jul 2021; status: completed.
02
Drugs
amphotericin b cholesteryl sulfate complex
03
Conditions
Invasive mold disease (IMD)talaromycosis
Beyond the preview
Go deeper on NCT07239765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07239765.